Patients with tumor mutations in the erythroblastic leukemia viral oncogene homolog (ErbB) family, including EGFR and ErbB2, had a significantly shorter disease-free survival than those with wild-type EGFR or ErbB2. This evidence concerns the gene ERBB2 and neoplasm.